0
S$0.00
0 items
No products in the cart.

Hepatocellular Carcinoma (HCC)

The Fifth Most Common Malignancy in the World

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and ranked as the third cancer-related mortality globally. Morbidity has increased in recent years, with 630,000 new cases in males and 273,000 new cases in females per year. Ablation is best used for tumors no larger than 4 cm across.

Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma - a Clinical Viewpoint

  • Alessandro Grasso, Anthony F Watkinson, Jonathan M Tibballs, Andrew K Burroughs
  • Liver Transplantation and Hepatobiliary Unit & Department of Radiology, Royal Free Hospital, London, UK

Outcome of No-Touch RFA for Small HCC: A Multicenter Clinical Trial

  • Dong Ho Lee, Min Woo Lee, Pyo Nyun Kim , Young Joon Lee, Hee Sun Park, Jeong Min Lee
  • RSNA Published Online: Jul 27, 2021

Treatment Outcomes of Percutaneous RFA for HCC: Effects of the Electrode Type and Placement Method

  • Jiyeon Park, Min Woo Lee, Soo Hyun Ahn, Seungchul Han, Ji Hye Min, Dong Ik Cha, Kyoung Doo Song, Tae Wook Kang, Hyunchul Rhim
  • Korean J Radiol 2023;24(8):761-771

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial)

Need Proctorship? Contact us at (+65) 6748 9686.

Connect With Us

Facebook-square Linkedin

Supported Payment Methods

© 2024 Medaid Solutions Private Limited. All Rights Reserved.
Website by Creative eWorld Pte Ltd.

Become An Insider

Get first access to our latest products, promotion & events.

Connect With Us

Facebook-square Instagram Twitter

Supported Payment Methods